Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Bruno Sangro(Clinica Universidad de Navarra), Alexandra Heurgué(Hôpital Robert-Debré), Tu Van Dao(Vietnam National Children's Hospital), В. В. Бредер, Ann‐Lii Cheng(National Taiwan University), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Marı́a Varela(Universidad de Oviedo), Masatoshi Kudo(Kindai University), Alejandra Negro(AstraZeneca (Japan)), Shukui Qin(81th Hospital of PLA), Sajid Ali(Bacha Khan University), Stephen L. Chan(Chinese University of Hong Kong), John F. Kurland(AstraZeneca (Netherlands)), Enrico N. De Toni(LMU Klinikum), Junji Furuse(Kanagawa Prefectural Hospital Organization), Sérgio Jobim Azevedo(Hospital de Clínicas de Porto Alegre), Kabir Mody(Mayo Clinic in Florida), Lorenza Rimassa(Humanitas University), Peter R. Galle(Johannes Gutenberg University Mainz), Alexander Vasilyev(Russian Railways), Michelle Marcovitz(AstraZeneca (Japan)), Vincent C. Tam(University of Calgary), Wattana Sukeepaisarnjaroen(Khon Kaen University), Thomas Yau(University of Hong Kong), Philip He(AstraZeneca (Japan)), George Lau(Humanity & Health), Yuriy Ostapenko(National Cancer Institute), Mallory Makowsky(AstraZeneca (Japan)), Satheesh Chiradoni Thungappa(Sri Venkateshwaraa Medical College Hospital and Research Centre), Yoon‐Koo Kang(Ulsan College)
Cited by 1,419
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k